CD79A and Miyoshi myopathy: Patients with this mutation exhibit a unique biological feature compared to other MM cell types, characterized by an increase in the presence of the B-cell lineage membrane protein CD20, higher levels of the B-cell receptor CD79a, and a decrease in the expression of both CD38 and CD56 [6,7].